Primary Progressive Aphasia (PPA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Primary Progressive Aphasia Emerging Therapy and TPP Insights

Thelansis’s “Primary Progressive Aphasia (PPA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Primary Progressive Aphasia (PPA) Overview

Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by progressive decline in language function as the predominant early clinical feature, with three major variants that differ in their clinical and pathological associations. Over time, some patients develop broader cognitive, behavioral, or motor impairment. PPA is most commonly associated with Alzheimer’s disease pathology, FTLD-tau, or FTLD-TDP-43, making accurate biomarker-based etiologic diagnosis increasingly important for treatment selection. There is currently no disease-modifying therapy specifically approved for PPA, and management remains centered on speech-language therapy, communication strategies, and treatment of associated behavioral or neurological symptoms. Speech-language interventions can improve or preserve functional communication even though they do not stop neurodegeneration. For patients with biomarker-confirmed Alzheimer’s pathology, Alzheimer’s-directed therapies may be considered, although pivotal trials were not designed specifically for PPA. Meanwhile, pathology-specific research is emerging, including TDP-43-directed approaches such as verdiperstat in semantic-variant PPA. For stakeholders, PPA represents a challenging but potentially important precision-neurodegeneration opportunity where biomarker-defined diagnosis must converge with pathology-specific disease modification.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)